On June 25, the FDA approved London-based GW Pharma’s Epidiolex, a drug containing CBD as its active ingredient, to treat two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients 2 years old and older.
This is a major win for a cannabis market that continues to entice investors.
According to a recent report by Hexa Research, the U.S. medical cannabis market is projected to reach $19.48 billion by 2024.
We have now discovered a little known CBD company CIIX (Chineseinvestors.com, Inc.) out of Los Angeles, CA.. Start doing your own research on CIIX immediately before the crowd discovers it. CIIX could be on everyone’s screen a week from now, you are hearing it here first. CIIX has an exciting CBD business, through its wholly owned subsidiaries ChineseHempOil, Inc. and its websites ChineseCBDOil.com and ChineseHempOil.com for online retail, and direct sales of hemp based CBD products. CIIX is planning a major revenue expansion domestically for its CBD/Hemp based business. Those that discover CIIX now should be very happy in the future.
A few companies with important news in the sector include: Chineseinvestors.com, Inc. (CIIX), CV Sciences, Inc. (CVSI), Aurora Cannabis (ABCFF), GW Pharmaceuticals, Inc. (GWPH), and Insys Therapeutics, Inc. (INSY).
Chineseinvestors.com, Inc. (CIIX)
Market Cap: $11.07M Share Price: $0.39
ChineseInvestors.com (CIIX), a premier financial info website for Chinese-speaking investors, is engaged in retail, online and direct sales of hemp-based products and other health related products among several other sectors, one being the crypto market. The company recently
announced the official launch of its new cryptocurrency trading courses offered through its newly established Bitcoin Trading Academy LLC. With its feet in two of the hottest markets around, CBD and Crypto, CIIX is beginning to turn heads in the investment community.
CV Sciences, Inc. (CVSI)
Market Cap: $282.86M Share Price: $3.12
CV Sciences, Inc. is a supplier and manufacturer of hemp-based phytocannabinoids including cannabidiol (CBD) oil and developer of specialty pharmaceutical therapeutics. The Company recently had news showing unaudited second quarter 2018 revenue. Second quarter 2018 revenue is expected to be USD 12.3 Million, up over 200% to the second quarter of 2017. Investors have hopped on this news pushing CVSI into the green over the past few sessions.
Aurora Cannabis (ABCFF)
Market Cap: $3.11B Share Price: $5.45
Another CBD company receiving investor interest from recent new is Aurora Cannabis Inc. (ACBFF). The company recently received a Letter of Intent to establish one of the first medical cannabis production facilities in Malta. The Company received a Letter of Intent from Malta Enterprise for the establishment of a seed-to-pharma cannabis operation, including the construction of a hybrid production facility that will be focused predominantly on the production of oils and derivatives. Operations will be carried out by a new company, to be formed by Aurora and its local partner Cherubino Ltd., the largest pharmaceutical wholesaler in Malta with an operating history of over 100 years. Aurora will be the majority shareholder in the new venture.
GW Pharmaceuticals, Inc. (GWPH)
Market Cap: $3.80B Share Price: $135.07
Referenced earlier in this report, GW Pharmaceuticals, Inc. (GWPH), has investors on the edge of their seats. The company is preparing to announce their fiscal 3rd quarter results August 7th on a conference call at 4:30 pm. The stock’s performance has been mixed as investors prepare for the call.
Insys Therapeutics, Inc. (INSY)
Market Cap: $491.56M Share Price: $6.66
Not all CBD companies have had positive news, Friday, Insys Therapeutics, Inc announced the U.S. Food and Drug Administration declined to approve its opioid painkiller, citing potential safety concerns. Insys’ treatment is an under-the-tongue spray formulation of the opioid buprenorphine that was under review to treat moderate-to-severe pain. Despite the news, the stock has started to rebound as investors look for the company to rebound from this news.
With investor interest squarely growing on the CBD, lesser known quantities such as CIIX may be prime for an influx of attention making this a good time for investors to consider CIIX.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and one thousand dollars total by Regal Consulting. LLC, for news commentary articles for CIIX. CIIX and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article’s distribution.
For Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States